{"id":17561,"date":"2014-03-18T13:55:35","date_gmt":"2014-03-18T17:55:35","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=17561"},"modified":"2014-03-18T13:55:35","modified_gmt":"2014-03-18T17:55:35","slug":"gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561","title":{"rendered":"Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 03\/17\/2014 (wallstreetpr) &#8211;\u00a0Sovaldi from <b>Gilead Sciences, Inc. (NASDAQ:GILD)<\/b> expects to become one of the best-selling medicine to treat Hepatitis C virus (HCV). The successful launch of the product had significant impacts on company\u2019s overall product sales.<\/p>\n<p style=\"text-align: justify;\"><b>Market<\/b><\/p>\n<p style=\"text-align: justify;\">Around 2 million people in the U.S. suffer from Hepatitis C and the number will continue to rise with increasing infections through transmission (blood-to-blood transfusion). Though several medicines are available in the market, however, potential side effects have reduced the number to few drugs. As a result, companies are focusing on development of novel treatment options to treat with HCV.<\/p>\n<p style=\"text-align: justify;\"><b>Sovaldi<\/b><\/p>\n<p style=\"text-align: justify;\">Sovaldi, one of such HCV treatment drug, got the approval from the U.S. Food and Drug Administration (FDA) in December 2013. The drug has higher efficiency and no instances of side effects. It also has 90% success rate and shorter duration compared to others which require one year treatment.\u00a0 Conversely, the drug has an affordability issue across the medical fraternity including patients and insurance providers. At present, the price of Sovaldi is at $84,000 for a 12 weeks treatment which is nearly impossible. But, the efficacy of the drug will have significant impact across the therapeutic market.<\/p>\n<p style=\"text-align: justify;\"><b>Potential Impact<\/b><\/p>\n<p style=\"text-align: justify;\">Since its launch, Gilead Sciences, Inc. (NASDAQ:GILD) had already reported sales of $139 million, which is mainly driven by patients demand and efficiency in clinical trials. Furthermore, the FDA approved Sovaldi for combination therapy along with other agents for the treatment of Hepatitis C. By and large, the therapeutic market is optimistic on Sovaldi and expects that the drug will report sales of $8 billion by 2015.<\/p>\n<p style=\"text-align: justify;\">Gilead Sciences, Inc. (NASDAQ:GILD) already dominates the HCV market with wide range of marketed products. And, Sovaldi will further improve its antiviral product sales. Company expects significant growth in revenue and earnings along with Sovaldi in the coming years.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 03\/17\/2014 (wallstreetpr) &#8211;\u00a0Sovaldi from Gilead Sciences, Inc. (NASDAQ:GILD) expects to become one of the best-selling medicine to treat Hepatitis C virus (HCV). The [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":17566,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1978,1522],"stock_ticker":[],"class_list":["post-17561","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-gilead-sciences-inc-nasdaqgild","tag-nasdaqgild","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 03\/17\/2014 (wallstreetpr) &#8211;\u00a0Sovaldi from Gilead Sciences, Inc. (NASDAQ:GILD) expects to become one of the best-selling medicine to treat Hepatitis C virus (HCV). The [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-03-18T17:55:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability\",\"datePublished\":\"2014-03-18T17:55:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561\"},\"wordCount\":314,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg\",\"keywords\":[\"Gilead Sciences Inc (NASDAQ:GILD)\",\"NASDAQ:GILD\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561\",\"name\":\"Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg\",\"datePublished\":\"2014-03-18T17:55:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg\",\"width\":1024,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability - Wall Street PR","og_description":"Boston, MA 03\/17\/2014 (wallstreetpr) &#8211;\u00a0Sovaldi from Gilead Sciences, Inc. (NASDAQ:GILD) expects to become one of the best-selling medicine to treat Hepatitis C virus (HCV). The [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-03-18T17:55:35+00:00","og_image":[{"width":1024,"height":380,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability","datePublished":"2014-03-18T17:55:35+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561"},"wordCount":314,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg","keywords":["Gilead Sciences Inc (NASDAQ:GILD)","NASDAQ:GILD"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561","url":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561","name":"Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg","datePublished":"2014-03-18T17:55:35+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/gilead-sciences.jpg","width":1024,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgilds-hepatitis-drug-efficiency-over-affordability-17561#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences, Inc. (NASDAQ:GILD)\u2019s Hepatitis drug: Efficiency Over Affordability"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/17561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=17561"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/17561\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/17566"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=17561"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=17561"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=17561"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=17561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}